Trial Profile
A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms ABC-X; ABC-X Study
- 31 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 26 Oct 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 13 May 2021 New source identified and integrated European Clinical Trials Database (EudraCT2020-005647-24).